Significant downregulation of MYCN transcripts (p < 0.05) was detected in DpC-treated SK-N-BE(2) cells (Figure 7C), which suggests that DpC might exert its activity against neuroblastoma cells via transcriptional inhibition of MYC oncoproteins, which are major drivers of aggressive neuroblastoma. This evidence concerns the gene MYCN and neuroblastoma.